Ultragenyx is trading 5.5% up at $13.59, alongside a broad biotechnology rebound and stronger overall risk appetite.
- No new company-specific announcement clearly explains the September 17, 2026 move.
- Recent negative coverage involved the September 2 Angelman syndrome trial failure, which had already pressured shares earlier in September.
- Reuters reported the late-stage treatment missed its main goal.